2025 Q3 -tulosraportti
Vain PDF
20 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
4 373
Myynti
Määrä
1 012
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 150 | NON | SSWM | ||
| 249 | NON | SSWM | ||
| 465 | NON | SSWM | ||
| 357 | NON | ENS | ||
| 1 000 | NON | ENS |
Ylin
12,32VWAP
Alin
11,96VaihtoMäärä
0,2 16 304
VWAP
Ylin
12,32Alin
11,96VaihtoMäärä
0,2 16 304
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 11 159 | 2 154 | +9 005 | 2 154 |
| Avanza Bank AB | 1 168 | 870 | +298 | 285 |
| Swedbank AB | 0 | 449 | −449 | 0 |
| SSW Market Making GmbH | 3 977 | 5 364 | −1 387 | 0 |
| Danske Bank A/S | 0 | 1 883 | −1 883 | 0 |
| Skandinaviska Enskilda Banken AB | 0 | 5 584 | −5 584 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 0 | 5 584 | −5 584 | 0 |
| Danske Bank A/S | 0 | 1 883 | −1 883 | 0 |
| SSW Market Making GmbH | 3 977 | 5 364 | −1 387 | 0 |
| Swedbank AB | 0 | 449 | −449 | 0 |
| Avanza Bank AB | 1 168 | 870 | +298 | 285 |
| Nordnet Bank AB | 11 159 | 2 154 | +9 005 | 2 154 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 15.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 päivä sitten1 päivä sitten
1 päivä sitten1 päivä sitten
17.11.17.11.
·13.11.It's quite absurd that it stays where it stays - production is underway, their CMO StaQ Pharma is owned, among others, by a number of children's hospitals - i.e., by Cessatech's primary customers. They must be able to sell almost everywhere to all hospitals in the USA, we are only waiting for the trucks to leave the factory - that is of course crucial, and sales figures are what will show it, but really - it's as if there are zero expectations for anything here, even though all signs point to something big, with approx. 0 risk. Is it because it's biotech, so people have burned their fingers too many times, or? I would say the share price should rise now, and then again (a lot), with good sales figures, next year.
·13.11.Agreed. Normally, the price will reflect the potential revenues compared to the probability of them being realized. The probability of them coming to market is high for a drug (> 50% if one is very cautious). After this, one can speculate whether sales will end up at 200 - 400 mill USD as Ventil has suggested or less. Next, add revenue from the EU once the product is approved there. In addition to the value of the other development projects in their portfolio. But if Cessatech and their partners succeed reasonably well in fulfilling the potential for CT 001, the price could, by quick mental arithmetic, end up at 200 - 300 kr when sales take off. If one sets the probability of them reaching that point at 50%, a future price target of 100 - 150 kr is not unrealistic. And that stock can currently be bought for 11 - 12 kr (with a few months until expected launch). Or put another way, the confidence that Cessatech will achieve sales roughly in line with Ventis’ prediction is estimated, based on the current stock price, at 4 - 6%. It must undeniably be said to be somewhat on the conservative side.·18.11.Thanks for the information regarding the USA potential. The narrative only gets better because of it. In the EU, CT-01 must first be approved by the EU. It typically takes 12-15 months depending on questions/answers in the procedure. Since they submitted in September, they will probably get an approval in Q4 and can launch in the first countries by the end of 2026. However, for some countries, negotiations and subsidy rules must be initiated, so I don't expect much sales before 2027. I also think that it will primarily be the USA that drives the business case.
·12.11.5800 shares traded the day before the financial report. It seems like everything that needs to be priced in has been priced in. Yes, but it will be exciting tomorrow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
20 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sitten
- 1 päivä sitten1 päivä sitten
- 17.11.17.11.
- ·13.11.It's quite absurd that it stays where it stays - production is underway, their CMO StaQ Pharma is owned, among others, by a number of children's hospitals - i.e., by Cessatech's primary customers. They must be able to sell almost everywhere to all hospitals in the USA, we are only waiting for the trucks to leave the factory - that is of course crucial, and sales figures are what will show it, but really - it's as if there are zero expectations for anything here, even though all signs point to something big, with approx. 0 risk. Is it because it's biotech, so people have burned their fingers too many times, or? I would say the share price should rise now, and then again (a lot), with good sales figures, next year.·13.11.Agreed. Normally, the price will reflect the potential revenues compared to the probability of them being realized. The probability of them coming to market is high for a drug (> 50% if one is very cautious). After this, one can speculate whether sales will end up at 200 - 400 mill USD as Ventil has suggested or less. Next, add revenue from the EU once the product is approved there. In addition to the value of the other development projects in their portfolio. But if Cessatech and their partners succeed reasonably well in fulfilling the potential for CT 001, the price could, by quick mental arithmetic, end up at 200 - 300 kr when sales take off. If one sets the probability of them reaching that point at 50%, a future price target of 100 - 150 kr is not unrealistic. And that stock can currently be bought for 11 - 12 kr (with a few months until expected launch). Or put another way, the confidence that Cessatech will achieve sales roughly in line with Ventis’ prediction is estimated, based on the current stock price, at 4 - 6%. It must undeniably be said to be somewhat on the conservative side.·18.11.Thanks for the information regarding the USA potential. The narrative only gets better because of it. In the EU, CT-01 must first be approved by the EU. It typically takes 12-15 months depending on questions/answers in the procedure. Since they submitted in September, they will probably get an approval in Q4 and can launch in the first countries by the end of 2026. However, for some countries, negotiations and subsidy rules must be initiated, so I don't expect much sales before 2027. I also think that it will primarily be the USA that drives the business case.
- ·12.11.5800 shares traded the day before the financial report. It seems like everything that needs to be priced in has been priced in. Yes, but it will be exciting tomorrow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
4 373
Myynti
Määrä
1 012
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 150 | NON | SSWM | ||
| 249 | NON | SSWM | ||
| 465 | NON | SSWM | ||
| 357 | NON | ENS | ||
| 1 000 | NON | ENS |
Ylin
12,32VWAP
Alin
11,96VaihtoMäärä
0,2 16 304
VWAP
Ylin
12,32Alin
11,96VaihtoMäärä
0,2 16 304
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 11 159 | 2 154 | +9 005 | 2 154 |
| Avanza Bank AB | 1 168 | 870 | +298 | 285 |
| Swedbank AB | 0 | 449 | −449 | 0 |
| SSW Market Making GmbH | 3 977 | 5 364 | −1 387 | 0 |
| Danske Bank A/S | 0 | 1 883 | −1 883 | 0 |
| Skandinaviska Enskilda Banken AB | 0 | 5 584 | −5 584 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 0 | 5 584 | −5 584 | 0 |
| Danske Bank A/S | 0 | 1 883 | −1 883 | 0 |
| SSW Market Making GmbH | 3 977 | 5 364 | −1 387 | 0 |
| Swedbank AB | 0 | 449 | −449 | 0 |
| Avanza Bank AB | 1 168 | 870 | +298 | 285 |
| Nordnet Bank AB | 11 159 | 2 154 | +9 005 | 2 154 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 15.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: Quartr
2025 Q3 -tulosraportti
Vain PDF
20 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 15.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sitten
- 1 päivä sitten1 päivä sitten
- 17.11.17.11.
- ·13.11.It's quite absurd that it stays where it stays - production is underway, their CMO StaQ Pharma is owned, among others, by a number of children's hospitals - i.e., by Cessatech's primary customers. They must be able to sell almost everywhere to all hospitals in the USA, we are only waiting for the trucks to leave the factory - that is of course crucial, and sales figures are what will show it, but really - it's as if there are zero expectations for anything here, even though all signs point to something big, with approx. 0 risk. Is it because it's biotech, so people have burned their fingers too many times, or? I would say the share price should rise now, and then again (a lot), with good sales figures, next year.·13.11.Agreed. Normally, the price will reflect the potential revenues compared to the probability of them being realized. The probability of them coming to market is high for a drug (> 50% if one is very cautious). After this, one can speculate whether sales will end up at 200 - 400 mill USD as Ventil has suggested or less. Next, add revenue from the EU once the product is approved there. In addition to the value of the other development projects in their portfolio. But if Cessatech and their partners succeed reasonably well in fulfilling the potential for CT 001, the price could, by quick mental arithmetic, end up at 200 - 300 kr when sales take off. If one sets the probability of them reaching that point at 50%, a future price target of 100 - 150 kr is not unrealistic. And that stock can currently be bought for 11 - 12 kr (with a few months until expected launch). Or put another way, the confidence that Cessatech will achieve sales roughly in line with Ventis’ prediction is estimated, based on the current stock price, at 4 - 6%. It must undeniably be said to be somewhat on the conservative side.·18.11.Thanks for the information regarding the USA potential. The narrative only gets better because of it. In the EU, CT-01 must first be approved by the EU. It typically takes 12-15 months depending on questions/answers in the procedure. Since they submitted in September, they will probably get an approval in Q4 and can launch in the first countries by the end of 2026. However, for some countries, negotiations and subsidy rules must be initiated, so I don't expect much sales before 2027. I also think that it will primarily be the USA that drives the business case.
- ·12.11.5800 shares traded the day before the financial report. It seems like everything that needs to be priced in has been priced in. Yes, but it will be exciting tomorrow.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
4 373
Myynti
Määrä
1 012
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 150 | NON | SSWM | ||
| 249 | NON | SSWM | ||
| 465 | NON | SSWM | ||
| 357 | NON | ENS | ||
| 1 000 | NON | ENS |
Ylin
12,32VWAP
Alin
11,96VaihtoMäärä
0,2 16 304
VWAP
Ylin
12,32Alin
11,96VaihtoMäärä
0,2 16 304
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 11 159 | 2 154 | +9 005 | 2 154 |
| Avanza Bank AB | 1 168 | 870 | +298 | 285 |
| Swedbank AB | 0 | 449 | −449 | 0 |
| SSW Market Making GmbH | 3 977 | 5 364 | −1 387 | 0 |
| Danske Bank A/S | 0 | 1 883 | −1 883 | 0 |
| Skandinaviska Enskilda Banken AB | 0 | 5 584 | −5 584 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 0 | 5 584 | −5 584 | 0 |
| Danske Bank A/S | 0 | 1 883 | −1 883 | 0 |
| SSW Market Making GmbH | 3 977 | 5 364 | −1 387 | 0 |
| Swedbank AB | 0 | 449 | −449 | 0 |
| Avanza Bank AB | 1 168 | 870 | +298 | 285 |
| Nordnet Bank AB | 11 159 | 2 154 | +9 005 | 2 154 |